Beyond its differential expression, EHHADH is increasingly recognized for its pathogenetic and/or prognostic significance in cancers such as hepatocellular carcinoma, osteosarcoma, colorectal carcinoma, and pituitary adenoma (17–20, 24). Here, EHHADH is linked to hepatocellular carcinoma.